Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 201519-07-2022
19-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated July 18, 2022 titled 'Zydus receives final approval from the USFDA for Efinaconazole Topical Solution'18-07-2022
Zydus Lifesciences Ltd - 532321 - Post Buyback Public Announcement
Post Buyback Public Announcement16-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated July 16, 2022 with regard to Notice of 27th Annual General Meeting of the Company published in the Financial Express16-07-2022
Zydus Lifesciences Ltd - 532321 - Reg. 34 (1) Annual Report.
Annual Report for the Financial Year ended on March 31, 202215-07-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the Listing Regulations15-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated July 14, 2022 with regard to Notice and information of 27th Annual General Meeting of the Company14-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated July 11, 2022 titled 'Zydus receives final approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets'11-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated July 8, 2022 titled 'Zydus has launched Sitaglyn(r) and Siglyn(r) (Sitagliptin), for the management of Type 2 diabetes'.08-07-2022
Zydus Lifesciences Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer05-07-2022